Literature DB >> 198568

Induction of simian virus 40 (SV40) transplantation immunity in mice by SV40-transformed cells of various species.

L W Law, K K Takemoto, M J Rogers, R C Ting.   

Abstract

Specific tumor rejection was obtained with the use of simian virus 40 (SV40)-transformed cells from several species including man, rat, ape, sheep, and hamster. Growth of the syngeneic sarcoma mKSA in BALB/c mice was strikingly inhibited following a single immunization with as few as 10(3) intact, viable cells. Non-SV40-transformed cells did not induce tumor rejection activity nor did SV40-transformed lines induce immunity against the 3-methylcholanthrene-induced sarcoma Meth A, syngeneic with BALB/c mice. A close relationship existed between the tumor rejection antigen, the tumor-specific transplantation antigen (TSTA) located on the plasma membrane, and the intranuclear tumor antigen (T-ag). Both were associated with the DNA sequence of the early region of the SV40 genome, and TSTA activity was found in the nucleus. However, we did not observe a close parallelism between T-ag activity and TSTA. Neverthesless, the results strongly suggested that TSTA, like T-ag, was encoded by the virus.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198568     DOI: 10.1093/jnci/59.5.1523

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Tumor-specific transplantation antigen: use of the Ad2+ND1 hybrid virus to identify the protein responsible for simian virus 40 tumor rejection and its genetic origin.

Authors:  G Jay; F T Jay; C Chang; R M Friedman; A S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

2.  BK virus-transformed inbred hamster brain cells. I. Status of the viral DNA and the association of BK virus early antigens with purified plasma membranes.

Authors:  E Beth; G Giraldo; R Schmidt-Ullrich; M M Pater; A Pater; G di Mayorca
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.